Blar i NTNU Open på forfatter "Asphaug, Lars"
-
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH- mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
Heggebø, Liv Cathrine; Borgen, Ida Maria Henriksen; Rylander, Hillevi; Kiserud, Cecilie E.; Nordenmark, Tonje Kristin Haug; Hellebust, Taran Annette Paulsen; Evensen, Morten Egeberg; Gustavsson, Magnus; Ramberg, Christina; Sprauten, Mette; Magelssen, Henriette; Blakstad, Hanne; Moorthy, Janani; Andersson, Karin; Raunert, Ingela; Henry, Thomas; Moe, Cecilie; Granlund, Carin; Goplen, Dorota; Brekke, Jorunn; Johannessen, Tor-Christian Aase; Solheim, Tora S; Marienhagen, Kirsten; Humberset, Øyvind; Bergström, Per; Agrup, Måns; Dahl, Ludvig; Gubanski, Michael; Gojon, Helene; Brahme, Carl-Johan; Rydén, Isabelle; Jakola, Asgeir Store; Vik-Mo, Einar O.; Lie, Hanne Cathrine; Asphaug, Lars; Hervani, Maziar; Kristensen, Ingrid; Rüegg, Corina Silvia; Olsen, Inge Christoffer; Ledal, Rolf J; Degsell, Eskil; Werlenius, Katja; Blomstrand, Malin; Brandal, Petter (Peer reviewed; Journal article, 2023)Abstract Introduction The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from ... -
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
Löffeler, Sven; Bertilsson, Helena Maria; Müller, Christoph Rainer; Aas, Kirsti; Haugnes, Hege Sagstuen; Aksnessæther, Bjørg Yksnøy; Pesonen, Maiju; Thon, Kristian; Tandstad, Torgrim; Murtola, Teemu; Poulsen, Mads Hvid Aaberg; Nordstrøm, Tobias; Vigmostad, Maria Nyre; Ottosson, Fredrik; Holmsten, Karin; Christiansen, Ola B.; Slaaen, Marit; Haug, Erik Skaaheim; Storås, Anne Holck; Asphaug, Lars; Rannikko, Antti; Brasso, Klaus (Peer reviewed; Journal article, 2024)Background Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs ...